How effective is shingles vaccine
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The currently recommended recombinant zoster vaccine (RZV, marketed as Shingrix) is highly effective at preventing shingles and its common complication postherpetic neuralgia, with clinical trials showing efficacy above 90% in older adults and real-world studies confirming strong protection for years after vaccination [1] [2] [3]. Effectiveness varies by age, immune status and whether the full two-dose series is completed, and long-term benefits beyond preventing shingles—such as reduced dementia or heart attack risk—are suggestive but not yet proven causal [3] [4] [5] [6].
1. How well it works in clinical trials: near-complete prevention in ideal conditions
Pivotal phase III trials demonstrated that the adjuvanted recombinant zoster vaccine reduced the risk of herpes zoster by roughly 97% versus placebo in adults 50 and older in ZOE trials and showed similarly high efficacy in older cohorts, establishing a benchmark of very high efficacy under trial conditions [2] [7].
2. Real-world effectiveness: strong protection but somewhat lower than trials
Large observational and claims-based studies report slightly lower but still robust vaccine effectiveness in routine use — for example, an 85.5% effectiveness estimate in a U.S. claims cohort and near-74% real-world effectiveness against herpes zoster in another analysis — confirming that Shingrix translates well outside trials [4] [8].
3. Duration of protection and waning: years of benefit but not immutable
Long-term follow-up data from trial extensions and manufacturer reports indicate high protection persisting for a decade in many recipients (e.g., ~79.7% efficacy six to 11 years post-vaccination in an end-of-trial analysis), and separate studies show sustained effectiveness over at least four years in large health-system populations [9] [3]. Nonetheless, older live-attenuated vaccines (Zostavax) showed substantial waning within a few years, and real-world estimates can vary with age and immune status [10] [11].
4. Two doses matter — completion and timing affect outcomes
Multiple analyses find that two doses of RZV provide significantly greater protection than a single dose, and missing the second dose reduces effectiveness; studies of older adults and Medicare data emphasize higher protection in those completing the series, even if the second dose is delayed [12] [13].
5. Effectiveness in older and immunocompromised people: reduced but meaningful
While efficacy remains high overall, effectiveness can be lower in those with weakened immune systems and in the very elderly; real-world work shows protection in immunocompromised people ranging from roughly 65% to the low 90s depending on condition, and age-related immunosenescence can modestly reduce vaccine impact though substantial protection often remains [3] [1] [4].
6. Beyond shingles: emerging associations and the limits of causation
Observational studies have linked shingles vaccination to lower dementia rates and reduced cardiovascular events, with analyses showing a roughly 20% lower dementia diagnosis rate in some cohorts and meta-analyses reporting ~16–18% lower risk of heart attack and stroke among vaccinated adults, but causal mechanisms remain unproven and residual confounding is a concern [5] [6].
7. Caveats, conflicts of interest, and how to interpret the data
Manufacturer press releases highlight impressive long-term and regional trial results that align with independent trials but carry inherent promotional framing; observational designs that suggest broader health benefits face biases because vaccinated people often differ in unmeasured health behaviors, and some subgroup analyses show inconsistent benefits across racial groups or settings [9] [5] [13].
8. Bottom line for public health impact
Taken together, randomized trials and large real-world studies paint a consistent picture: the recombinant shingles vaccine is highly effective at preventing shingles and its major complication when the two-dose series is completed, provides multi-year protection for most recipients, and likely yields population-level reductions in disease burden — while ancillary health benefits remain an active area of research requiring more rigorous causal study [2] [4] [3] [6].